ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES

ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES

Show other versions (1)

Studies data on new anticoagulants, direct oral thrombin inhibitor (dabigatran) and direct inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial fibrillation are presented. Effects of these drugs on cardiovascular events in atrial fibrillation are analyz...

Full description

Bibliographic Details
Main Authors: Z. M. Safiullina, S. V. Shalaev
Format: Article
Language:English
Published: Столичная издательская компания 2015-09-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
anticoagulants
direct oral thrombin inhibitor
direct inhibitor of coagulation factor xa
Online Access:https://www.rpcardio.online/jour/article/view/283
Description
Summary:Studies data on new anticoagulants, direct oral thrombin inhibitor (dabigatran) and direct inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial fibrillation are presented. Effects of these drugs on cardiovascular events in atrial fibrillation are analyzed based on the results of various studies. Prospects for further research are discussed.
ISSN:1819-6446
2225-3653

Similar Items